BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit growth accelerates

Q3 FY2026 gross profit of $819.23B rose 128700.0% year over year, ahead of the +32536.1% change in trailing-twelve-month gross profit. Sequentially, it rose 104006.8% from the prior quarter. Over 3 fiscal years it compounded at +16.0% a year.

Context

  • Gross profit amounted to 77.1% of revenue in FY2025, down 2.5 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +128700.0% holds above the trailing-twelve-month pace of +32536.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$819.23B+104006.8% QoQ
Last fiscal yearDec 2025
$2.48B+9.3% YoY
LTMSep 2026
$821.17B+32536.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+128700.0%——
1 year+9.3%——
3-year CAGR+16.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
2.48B USD
Year-over-year change
+9.3%
4-year CAGR
+15.9%

Gross Profit vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +32536.1% is the highest of 11, against a peer median of +12.1%.
  • Gross profit amounts to 79.9% of revenue for BMRN, versus a peer median of 84.6%.
BMRN Competitors
Gross Profit for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$821.17B USD+32536.1%+16.0%79.9%
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 2026$11.11B USD+9.9%+9.4%85.6%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$3.83B USD+86.0%+51.8%79.7%
ASNDAscendis Pharma A/SLTM Sep 2026€1.09B EUR+95.1%+147.0%90.6%
INSMInsmed IncorporatedLTM Jun 2026$947.34M USD+214.3%+36.3%83.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$942.72M USD-1.3%+17.4%98.2%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$828.57M USD-51.6%+36.4%82.1%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$665.62M USD+193.4%+85.5%93.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$559.44M USD+11.3%+19.0%83.6%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$394.98M USD-7.2%+66.0%60.7%
PHARPharming Group N.V.LTM Mar 2026$322.4M USD+13.0%+20.8%87.3%
Peer median (excluding BMRN) —+12.1%+36.3%84.6%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.85B2.1B2.42B2.85B3.22B
Cost of Revenue470.52M503.02M532.06M580.24M736.83M
Gross Profit1.38B1.59B1.89B2.27B2.48B
Gross Margin74.5%76.0%78.0%79.7%77.1%
Research & Development628.79M649.61M746.77M747.18M921.93M
Selling, General & Admin759.4M823.2M892.4M1.01B1.28B
Operating Expenses1.46B1.43B1.7B1.79B1.95B
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
EBITDA47.43M265.36M306.77M650.53M572.94M
EBITDA Margin2.6%12.7%12.7%22.8%17.8%
Operating Income(82.34M)160.97M185.77M484.21M533.48M
Operating Margin-4.5%7.7%7.7%17.0%16.6%
Interest Income10.48M18.03M58.34M74.88M74.9M
Interest Expense15.34M15.97M17.34M12.67M10.9M
Other Income / Expenses6.99M(11.4M)2.79M57.55M(51M)
Income Before Tax(75.35M)149.58M188.56M541.76M482.48M
Pre-Tax Margin-4.1%7.1%7.8%19.0%15.0%
Income Tax Expense(11.27M)8.02M20.92M114.9M133.58M
Net Income(64.08M)141.56M167.65M426.86M348.9M
Net Margin-3.5%6.8%6.9%15.0%10.8%
EPS (Basic)(0.35)0.760.892.251.82
EPS (Diluted)(0.35)0.750.882.211.80
Weighted Avg Shares182.85M185.27M187.83M190.03M191.79M
Weighted Avg Shares (Diluted)182.85M188.96M191.6M196.71M197.39M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.